Ucb, Inc. v. Actavis Laboratories Ut, Inc.

Case: 21-1924 Document: 72 Page: 1 Filed: 06/16/2023

NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit

______________________ June 16, 2023 ERRATA ______________________ Appeal No. 21-1924

UCB, INC., UCB PHARMA GMBH, LTS LOHMANN

THERAPIE-SYSTEME AG,

Plaintiffs-Appellants v.

ACTAVIS LABORATORIES UT, INC.,

Defendant-Appellee -------------------------------------------------

Appeal No. 21-2336

UCB, INC., UCB PHARMA GMBH, LTS LOHMANN

THERAPIE-SYSTEME AG,

Plaintiffs-Appellants v.

MYLAN TECHNOLOGIES INC.,

Defendant-Appellee ______________________

Decided: April 12, 2023 Precedential Opinion ______________________

Case: 21-1924 Document: 72 Page: 2 Filed: 06/16/2023 2 UCB, INC. v. ACTAVIS LABORATORIES UT, INC. Please make the following change to the caption in the opinion and judgment issued April 12, 2023, and the order granting an extension of time issued May 8, 2023: 1 UCB, INC., UCB PHARMA GMBH, LTS LOHMANN

THERAPIE-SYSTEME AG,

Plaintiffs-Appellants v. ACTAVIS LABORATORIES UT, INC.,

Defendant-Appellee ______________________

2021-1924 ______________________

Appeal from the United States District Court for the District of Delaware in No. 1:19-cv-00474-KAJ, Circuit Judge Kent A. Jordan.

----------------------------------------------- UCB, INC., UCB PHARMA GMBH, LTS LOHMANN

THERAPIE-SYSTEME AG,

Plaintiffs-Appellants v. MYLAN TECHNOLOGIES INC.,

Defendant-Appellee ______________________

2021-2336 ______________________

Appeal from the United States District Court for the District of Vermont in No. 2:19-cv-00128-cr, Judge Chris- tina Reiss.

1 The originating tribunal information has been cor- rected to state that Appeal No. 2021-2336 originated from the United States District Court for the District of Ver- mont.